<DOC>
	<DOCNO>NCT00331838</DOCNO>
	<brief_summary>The primary objective demonstrate dose-response Semuloparin sodium ( AVE5026 ) prevention Venous Thromboembolism [ VTE ] patient undergo total knee replacement [ TKR ] surgery . Secondary objective evaluate safety ( incidence major bleed ) AVE5026 , document efficacy safety AVE5026 post-operative regimen , assess pharmacokinetic parameter AVE5026 .</brief_summary>
	<brief_title>Prevention Venous Thromboembolism Patients Undergoing Elective Total Knee Replacement Surgery</brief_title>
	<detailed_description>The randomization take place first study drug injection . The total duration observation per participant 27-33 day surgery broken follow : - 4 10-day double-blind treatment period ; - Follow-up period Day 30 ± 3 surgery . Mandatory bilateral venography lower limb perform 5 11 day surgery .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Patient schedule undergo elective total knee replacement revision primary procedure perform ≥ 6 month prior study entry . Any major orthopedic surgery 3 month prior study entry ; Clinical sign symptom DVT PE within last 12 month know postphlebitic syndrome ; Known sensitivity iodine contrast dye ; Recent stroke myocardial infarction ; High risk bleeding ; Treatment antithrombotic agent within 7 day prior surgery ; Any contraindication Unfractionated Heparin Low Molecular Weight Heparin ; Pregnant nursing woman , woman childbearing potential use effective contraceptive method . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Prevention</keyword>
	<keyword>Venous Thrombosis</keyword>
	<keyword>Orthopedic Surgery</keyword>
</DOC>